{"job_id": "1c7fb5fc-a756-4160-8cdd-ff6733659e02", "brochure_id": "1c7fb5fc-a756-4160-8cdd-ff6733659e02", "brochure_name": "Diva Brochure_6 Feb (1) (2).pdf", "status": "completed", "results": [{"statement": "DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed\nTomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter;\nCVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter, CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted\nCentral Catheter; ECG: Electrocardiogram", "reference_no": "1", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: Background: The term \"difficult intravenous access\" (DIVA) is commonly used but not clearly defined.|Repeated attempts at peripheral intravenous catheter (PIVC) insertion can be a traumatic experience for patients, leading to sub-optimal clinical and economic outcomes.", "validation_result": "Supported", "page_location": "Page 1, Abstract", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "DIVA: A Growing Challenge\nin the Asia Pacific Region. Difficult Intravenous Access (DIVA) refers to the challenge of securing IV access due to:\u00b9", "reference_no": "1", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: The term \"difficult intravenous access\" (DIVA) is used\nin the literature to describe this patient population, but\nthere is inconsistency in how DIVA is defined, and to our\nknowledge no systematic search has been undertaken to\nevaluate these definitions.", "validation_result": "Supported", "page_location": "Page 2, paragraph 1", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "For DIVA Patients, Every Stick Matters. Proactively identifying and managing DIVA patients can help:\u00b2", "reference_no": "2", "reference": "Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015;38(3):189-203. doi:10.1097/NAN.0000000000000100.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 2.Helm RE, 2015.pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "Throughout the document", "confidence_score": 0.2, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Keeping DIVA patients S.A.F.E.. The optimal DIVA management strategy involves screening all patients prior to any\nattempted vascular access device insertion.\u00b2", "reference_no": "2", "reference": "Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015;38(3):189-203. doi:10.1097/NAN.0000000000000100.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 2.Helm RE, 2015.pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "DIVA: A Growing Challenge\nin the Asia Pacific Region. While nearly 90% of hospital inpatients need vascular access, DIVA affects over one-third of\nadults and up to 50% of children - often resulting in repeated, painful attempts. 2,3 BD market", "reference_no": "3", "reference": "Sou V, McManus C, Mifflin N, Frost SA, Ale J, Alexandrou E. A clinical pathway for the management of difficult venous access. BMC Nursing. 2017;16(1). doi:https://- doi.org/10.1186/s12912-017-0261-z.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 3.Sou2017.pdf: Over a third of adults and up to half of the children that present to hospital who require a PIVC, are reported to have difficult venous access (DiVA) [4, 5].|Patients with DiVA may undergo multiple, painful attempts to gain peripheral venous access [7].", "validation_result": "Supported", "page_location": "Page 1, Background section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "DIVA: A Growing Challenge\nin the Asia Pacific Region. BD market\nresearch reports that DIVA patients comprise 20% of the population in Japan and South Korea,\nand 24% in Australia. The majority of DIVA cases are managed by vascular access teams (e.g.,\n61% across Australia and New Zealand).4,5", "reference_no": "4,5", "reference": "", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 5.NSC_BD_Project Bolt_Quantitative Research Report_20211213.pdf: Those in the VAT team, unsurprisingly, have the greatest proportion of DIVA patients, a third of whom are obese patients.", "validation_result": "Supported", "page_location": "Page 33, Proportion of Patients with DIVA & Types of DIVA Patients", "confidence_score": 0.75, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "MEDIUM"}, {"statement": "Risk Factors. History of IV access\nfor chemotherapy and\nother drugs 1,3", "reference_no": "1,3", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: Risk factors. The risk factors for DIVA reported across the publications align with the common themes reported for the definition of DIVA.|A history of difficult IV access was also regularly associated with DIVA (six publications) [theme 3].\n- 3.Sou2017.pdf: Patients with chronic and complex\ndisease, who have a history of intravenous drug use, are\nobese or malnourished or who have received chemother-\napy, are cohorts known to suffer from DiVA [5\u20137].", "validation_result": "Supported", "page_location": "Page 3, Risk factors section | Page 1, Background section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Risk Factors. Non-visible or\nnon-palpable veins 1,3", "reference_no": "1,3", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: Of these, themes 1-3 (failed attempts at PIV access using traditional technique; based on physical examination findings for example no visible or palpable veins; and personal history of DIVA) were covered by all but one publication.\n- 3.Sou2017.pdf: Difficult venous access is characterised by non-visible and non-palpable veins where a highly experienced oper- ator is required with the use of technological aids to insert a vascular device [6].", "validation_result": "Supported", "page_location": "Page 1, Abstract, Results section | Page 1, Background section, paragraph 2", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Risk Factors. Chronic health conditions\nsuch as diabetes, obesity\nor malnutrition 1,3", "reference_no": "1,3", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: Risk factors. The risk factors for DIVA reported across the publications align with the common themes reported for the definition of DIVA. |Although there was great variability in the factors proposed, significant indicators included vein characteristics (palpability, visibility, poor vein condition, vein diameter, veins with many valves) (seven publications) [theme 2]; patient age (six publications); arthrometric values (patients classed as obese or underweight) (five publications); chronic health conditions (IV drug abuse, edema, cancer chemotherapy, diabetes, sickle cell disease, end-stage renal disease) (four publications) [theme 4]; gender (female) (four publications).\n- 3.Sou2017.pdf: Patients with chronic and complex\ndisease, who have a history of intravenous drug use, are\nobese or malnourished or who have received chemother-\napy, are cohorts known to suffer from DiVA [5\u20137].", "validation_result": "Supported", "page_location": "Page 3, Risk factors section | Page 1, Background section", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Understanding the Burden of DIVA. Patients with a history of DIVA are at almost 5x greater risk of experiencing this difficulty again.6", "reference_no": "6", "reference": "Rodriguez-Calero MA, de Pedro-Gomez JE, Molero-Ballester LJ, et al. Risk Factors for Difficult Peripheral Intravenous Cannulation. The PIVV2 Multicentre Case-Control Study. Journal of Clinical Medicine. 2020;9(3):799. doi:https://doi.org/10.3390/-jcm9030799.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 6.Rodriguez,2020.pdf: Patients with a previous history of DPIVC are at almost five times greater risk of experiencing this difficulty again.", "validation_result": "Supported", "page_location": "Page 20, Discussion section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Understanding the Burden of DIVA. Increase in costs and\ninefficient use of resources 1", "reference_no": "1", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: Ultimately, detrimental clinical outcomes can result in increased costs and inefficient use of resources.", "validation_result": "Supported", "page_location": "Page 1, Introduction", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Understanding the Burden of DIVA. Increased patient pain\u00b3", "reference_no": "3", "reference": "Sou V, McManus C, Mifflin N, Frost SA, Ale J, Alexandrou E. A clinical pathway for the management of difficult venous access. BMC Nursing. 2017;16(1). doi:https://- doi.org/10.1186/s12912-017-0261-z.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 3.Sou2017.pdf: Patients with DiVA may undergo multiple, painful at-tempts to gain peripheral venous access [7]. | This in turn, results in further painful, and often unsuccessful attempts to gain alternate peripheral venous access, leading to vessel damage and venous depletion [12]. | Patients reported a much higher level of pain with can-nulation attempts prior to referral for ultrasound guid-ance, some experienced severe pain with nearly a quarter (23.3%) of patients reporting a pain score of 10/10.", "validation_result": "Supported", "page_location": "Page 1, Background section | Page 2, paragraph 1 | Page 6, paragraph 3", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Keeping DIVA patients S.A.F.E.. Consider key risk factors using the SAFE rule\u2079", "reference_no": "9", "reference": "Bahl A, Alsbrooks K, Kelly Ann Zazyczny, Johnson S, Hoerauf K. An Improved Definition and SAFE Rule for Predicting Difficult Intravascular Access (DIVA) in Hospitalized Adults. Journal of Infusion Nursing. 2024;47(2):96-107. doi:https://doi.org/10.1097/nan.0000000000000535", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 9.Bahl A,2024.pdf: Using the 5 variables the primary analysis identified as significant (vein palpability, vein visibility, history of DIVA, history of IV drug abuse, and obesity) an acronym-based mnemonic guideline was created for clinical use (SAFE): See, Ask, Feel, Evaluate BMI (Figure 4).|The SAFE rule incorporates the best available evidence about risk factors for DIVA and is intended to encourage the recognition of DIVA prior to the first PIVC insertion attempt.", "validation_result": "Supported", "page_location": "Page 19, right column, last paragraph", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Goals of Care in DIVA Patients. \u2022 Prevent unnecessary escalation to more invasive products, delays\nin therapy and other complications. 10", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "Goals of Care in DIVA Patients. \u2022 Reduce clinician stress and workflow inefficiencies by decreasing\nthe number of vascular access attempts.10", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "Goals of Care in DIVA Patients. \u2022 Alleviate the substantial economic burden associated with DIVA. 10", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "Goals of Care in DIVA Patients. Early DIVA detection may help identify patients at risk of multiple cannulation\nattempts, enabling timely venous assessment and informed device selection based\non vein condition and therapy needs. This approach can improve first-stick success,\npreserve vein health, and align with the goals of care.\u00b9", "reference_no": "1", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: The evidence-driven definition also includes \"two or more failed attempts.\" Ideally, multiple failed attempts would not form part of a formal DIVA definition or escalation pathway; this would be replaced by standardized clinical assessment of venous anatomy and patient history to ensure that DIVA patients are identified before the first cannulation attempt. | This supports a patient-centric approach; by basing assessment on a known history of DIVA and clinical assessment of the vasculature and co-morbidities, unnecessary patient pain can be avoided, promoting escalation prior to attempting potentially unsuccessful IV access.", "validation_result": "Supported", "page_location": "Page 5, Discussion section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Device selection should always be based on patient assessment and device indications.1", "reference_no": "1", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: Guidance from the Infusion Nurses Society (INS) also recognizes the harms caused by multiple unsuccessful attempts; the INS recommends that PIVC insertion is restricted to no more than two attempts per clinician.51|Following two unsuccessful attempts, they recommend escalation to a clinician with a higher skill level, or use of alternative routes of administration.", "validation_result": "Supported", "page_location": "Page 5, Discussion section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Non-vesicant or non-irritant\nOsmolarity < 900 mOsm/L*\n(Peripheral recommended) 11,12", "reference_no": "11,12", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 11.INS 2024.pdf: Assess the patient's medical history (including previous vascular access) to determine the need for vascular visualization technology to assist in locating appropriate peripheral intravenous or arterial insertion sites. Factors likely to increase difficulty of peripheral intravenous and intra-arterial insertion using observation and palpation only (known as landmark techniques) include, but are not limited to, the following1,2: (II) | Standard 25, Vascular Access Device Planning and Site Selection.\n- 12. Pittiruti, M.et Al. (2021_.pdf: In this regard, there is a wide consensus in the recent literature that vesicant drugs, solutions with low (<5) or high (>9) pH or very high osmolarity (>600mOsm/L), as well as any other solution with potential irritant effects on the vein wall by other mechanisms not involving pH or osmolarity, should be preferably delivered by a CVAD.", "validation_result": "Supported", "page_location": "Page S17, Section One: Infusion Therapy Practice, 2. SPECIAL PATIENT POPULATIONS, Practice Recommendations A. Considerations for neonatal and pediatric patients: b. Identify pediatric patients with difficult intravenous access (DIVA); utilize technology (eg, ultrasound, near infrared light) and ensure skill of clinicians to improve insertion success (see Standard 5, Competency and Competency Assessment; Standard 21, Vascular Visualization; Standard 25, Vascular Access Device Planning and Site Selection).1,8,11,12 (I) | Page 5, Section 2 - Indications", "confidence_score": 0.8500000000000001, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Length of therapy 11,12", "reference_no": "11,12", "reference": "", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 11.INS 2024.pdf: 25. Vascular Access Device\nPlanning and Site\nSelection", "validation_result": "Supported", "page_location": "Page 5, Table of Contents", "confidence_score": 0.85, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Irritant or vesicant\nOsmolarity > 900 mOsm/L*\n(Central recommended) 11,12", "reference_no": "11,12", "reference": "", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 12. Pittiruti, M.et Al. (2021_.pdf: In this regard, there is a wide consensus in the recent literature that vesicant drugs, solutions with low (<5) or high (>9) pH or very high osmolarity (>600mOsm/L), as well as any other solution with potential irritant effects on the vein wall by other mechanisms not involving pH or osmolarity, should be preferably delivered by a CVAD.10,33,34", "validation_result": "Supported", "page_location": "Page 5, Section 2 - Indications", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Length of therapy 11,12", "reference_no": "11,12", "reference": "", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 11.INS 2024.pdf: 25. Vascular Access Device\nPlanning and Site\nSelection", "validation_result": "Supported", "page_location": "Page 5, Table of Contents", "confidence_score": 0.85, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Short term\n< 7 days 12,13,14", "reference_no": "12,13,14", "reference": "", "matched_paper": "Multiple PDFs (2/3 support)", "matched_evidence": "- 13. Pittiruti, M.pdf: Short peripheral cannula\nSuperficial vein of the arm available\nNeeded for < 1 week\nIntra-hospital use\n- 14.Magall\u00f3n-Pedrera,,2020.pdf: The former are devices 3 to 6 cm long, usually inserted into the veins of the forearm, indicated as short-term venous accesses when the therapy is expected to last less than 6 days [8].", "validation_result": "Supported", "page_location": "Page 9, under the heading \"Peripheral VAD\" | Page 8, Peripheral venous access catheters", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Long term\u00b9\u00b9\n< 1 year\u00b9\u00b9", "reference_no": "11", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 11.INS 2024.pdf: None", "validation_result": "Not Found", "page_location": "", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Vascular Access Planning. Short term\n< 7 days11", "reference_no": "11", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 11.INS 2024.pdf: The specialty of infusion therapy encompasses a broad spectrum of patient care\nthat is singularly focused on patient safety, demonstrated through the compre-\nhensive management of all patient infusion needs, including 1) planning for the\nintended therapy, vascular access device (VAD) and site selection, and skillful VAD\ninsertion", "validation_result": "Supported", "page_location": "Page S7, Preface section", "confidence_score": 0.85, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Intermediate term\n1-4 weeks 11,13,14", "reference_no": "11,13,14", "reference": "", "matched_paper": "Multiple PDFs (2/3 support)", "matched_evidence": "- 13. Pittiruti, M.pdf: Needed for less than 4 wks\n- 14.Magall\u00f3n-Pedrera,,2020.pdf: Fig. 1.", "validation_result": "Supported", "page_location": "Page 9, under Peripheral VAD | Page 15, Figure 1", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Long term\u00b9\u00b9", "reference_no": "11", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 11.INS 2024.pdf: 25. Vascular Access Device\nPlanning and Site\nSelection", "validation_result": "Supported", "page_location": "Page 5, Table of Contents", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Venous assessment\u00b9\u00b9", "reference_no": "11", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 11.INS 2024.pdf: 25. Vascular Access Device\nPlanning and Site\nSelection\nS85", "validation_result": "Supported", "page_location": "Page 5, Table of Contents", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Venous assessment 11,12,13", "reference_no": "11,12,13", "reference": "", "matched_paper": "Multiple PDFs (2/3 support)", "matched_evidence": "- 11.INS 2024.pdf: 25. Vascular Access Device\nPlanning and Site\nSelection\n- 12. Pittiruti, M.et Al. (2021_.pdf: Both the EPIC guide-lines\n(EPIC=Evidence-based Prevention and\nInfection Control) and the Standards of Practice of\nINS (Infusion Nursing Society)10 recommend skin\nantisepsis with 2% chlorhexidine in 70% isopropyl\nalcohol before insertion of any PVAD, as well as\nsecurement and protection of the exit site with\ntransparent semipermeable membranes whenever\npossible.|Also - and this may be regarded as the\nmost relevant, habit-changing innovation both\nEPIC and INS recommend that peripheral venous\ncatheters should be re-sited only when clinically\nindicated (i.e. if complications occur) and not rou-\ntinely, as previously recommended).11,12", "validation_result": "Supported", "page_location": "Page 5, Table of Contents | Page 2, paragraph (1)", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. < 4 days 11,12", "reference_no": "11,12", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 11.INS 2024.pdf: b. Identify pediatric patients with difficult intrave- nous access (DIVA); utilize technology (eg, ultra- sound, near infrared light) and ensure skill of clinicians to improve insertion success (see Standard 5, Competency and Competency Assessment; Standard 21, Vascular Visualization; Standard 25, Vascular Access Device Planning and Site Selection).1,8,11,12 (I)\n- 12. Pittiruti, M.et Al. (2021_.pdf: Both EPIC and INS recommend that peripheral venous catheters should be re-sited only when clinically indicated (i.e. if complications occur) and not routinely, as previously recommended).11,12", "validation_result": "Supported", "page_location": "Page S17, Section One: Infusion Therapy Practice, 2. SPECIAL PATIENT POPULATIONS, Practice Recommendations | Page 2, Section (1)", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. < 7 days 15", "reference_no": "15", "reference": "Gonz\u00e1lez L\u00f3pez, J. L.et Al. (2014). Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. In Journal of Hospital Infection (Vol. 86, Issue 2, pp. 117\u2013126). doi.org/10.1016/j.jhin.2013.10.008.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 15. Gonz\u00e1lez L\u00f3pez 2014.pdf: Among PIVCs in place for \u226524 h, the median dwell time was 144.5 h for COS PIVCs [95% confidence interval (CI) 123.4\u2013165.6] and 99 h for MOS PIVCs (95% CI 87.2-110.8).", "validation_result": "Supported", "page_location": "Page 1, Summary section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Midline 11,13or\nPICC14,17", "reference_no": "11,13", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 11.INS 2024.pdf: Therefore, Site Selection was combined with VAD planning to become Standard 25, Vascular Access\nDevice Planning and Site Selection.\n- 13. Pittiruti, M.pdf: Midline catheter|Superficial vein of the arm unavailable US-guided insertion in deep veins of the arm)|Needed for > 3 weeks|Intra and extra-hospital use|PICC (\"brachially\" inserted CVC)", "validation_result": "Supported", "page_location": "Page S8, in the Preface section | Page 9", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. PICC14,17", "reference_no": "14,17", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: Regarding the different devices available for venous access in oncology, the survey results revealed that the parties responsible for cannulating each of them vary substantially. Thus, the majority of respondents (87.2%) said that the Nursing Department is responsible for implanting the peripheral catheter, while for the placement of PICCs, the parties responsible are mostly (80.0%) the Anesthesia or Vascular Surgery Departments or Venous Access Unit, followed by the Nursing Department (65.8%).\n- 17. PowerPICC Solo 2 catheter RN. Instruction For Use.2016.0741199 1602R.pdf: Bard PowerPicc Solo\u2122 2.Instruction For Use. Feb.2016.0741199 1602R.17.B", "validation_result": "Supported", "page_location": "Page 7, paragraph starting with 'Regarding the different devices' | References", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Midline 11", "reference_no": "11", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 11.INS 2024.pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Vascular Access Planning. PICC14,17", "reference_no": "14,17", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: Regarding the different devices available for venous access in oncology, the survey results revealed that the parties responsible for cannulating each of them vary substantially. Thus, the majority of respondents (87.2%) said that the Nursing Department is responsible for implanting the peripheral catheter, while for the placement of PICCs, the parties responsible are mostly (80.0%) the Anesthesia or Vascular Surgery Departments or Venous Access Unit, followed by the Nursing Department (65.8%).\n- 17. PowerPICC Solo 2 catheter RN. Instruction For Use.2016.0741199 1602R.pdf: Bard PowerPicc Solo\u2122 2.Instruction For Use. Feb.2016.0741199 1602R.17.B", "validation_result": "Supported", "page_location": "Page 7, paragraph starting with 'Regarding the different devices' | References", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. PICC16,17", "reference_no": "16,17", "reference": "", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 17. PowerPICC Solo 2 catheter RN. Instruction For Use.2016.0741199 1602R.pdf: Bard PowerPicc Solo\u2122 2.Instruction For Use. Feb.2016.0741199 1602R.16.\u0392.1|Bard PowerPicc Solo\u2122 2.Instruction For Use. Feb.2016.0741199 1602R.17.B", "validation_result": "Supported", "page_location": "References section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Long term\u00b9\u00b9", "reference_no": "11", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 11.INS 2024.pdf: 25. Vascular Access Device\nPlanning and Site\nSelection", "validation_result": "Supported", "page_location": "Page 5, Table of Contents", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Acute\nCICC14", "reference_no": "14", "reference": "Magall\u00f3n-Pedrera, I et Al. (2020). ECO-SEOM-SEEO safety recommendations guideline for cancer patients receiving intravenous therapy. In Clinical and Translational Oncology (Vol. 22, Issue 11, pp. 2049\u20132060). doi.org/10.1007/s12094-020-02347-1.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: In conclusion, both the venous access catheter selection algorithm and the proposed recommendations aim to respond to the needs revealed in clinical practice and to become an integrable tool in electronic prescription systems to offer homogeneous criteria for action in cancer patients that require venous access, optimizing the use of available health resources with the highest safety and quality of life for the patient.", "validation_result": "Supported", "page_location": "Page 2, Conclusions", "confidence_score": 0.85, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Tunnelled\nCVC11,14 or Port11", "reference_no": "11,14", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 11.INS 2024.pdf: 25. Vascular Access Device\nPlanning and Site Selection\n- 14.Magall\u00f3n-Pedrera,,2020.pdf: To this end, although there is no clear definition of what should be considered short- or long-term, a recent study sets the limit at 30 days [7], which allows recommendations to be made to use PICCs for durations of implantation shorter than this period and tunneled catheters or PICCs for longer durations of implantation [11].", "validation_result": "Supported", "page_location": "Page 5, Table of Contents | Page 9", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. PICC16,17", "reference_no": "16,17", "reference": "", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 17. PowerPICC Solo 2 catheter RN. Instruction For Use.2016.0741199 1602R.pdf: Bard PowerPicc Solo\u2122 2.Instruction For Use. Feb.2016.0741199 1602R.16.\u0392.1|Bard PowerPicc Solo\u2122 2.Instruction For Use. Feb.2016.0741199 1602R.17.B", "validation_result": "Supported", "page_location": "References section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Acute\nCICC11", "reference_no": "11", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 11.INS 2024.pdf: 25. Vascular Access Device\nPlanning and Site\nSelection", "validation_result": "Supported", "page_location": "Page 5, Table of Contents", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Vascular Access Planning. Tunnelled\nCVC11,14 or Port 11", "reference_no": "11,14", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 11.INS 2024.pdf: The specialty of infusion therapy encompasses a broad spectrum of patient care\nthat is singularly focused on patient safety, demonstrated through the compre-\nhensive management of all patient infusion needs, including 1) planning for the\nintended therapy, vascular access device (VAD) and site selection, and skillful VAD\ninsertion\n- 14.Magall\u00f3n-Pedrera,,2020.pdf: To this end, although there is no clear definition of what should be considered short- or long-term, a recent study sets the limit at 30 days [7], which allows recommendations to be made to use PICCs for durations of implantation shorter than this period and tunneled catheters or PICCs for longer durations of implantation [11].", "validation_result": "Supported", "page_location": "Page 7, Preface section | Page 9", "confidence_score": 0.875, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "PowerPICCT\u2122 Catheter. Provides efficient power injection. 18", "reference_no": "18", "reference": "BD PowerPICC: Instructions for Use (0735022).", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 18. 0735022 PowerPICC IFU.pdf: The PowerPICC* catheter is indicated for short or long term peripheral access to the central venous system for intravenous therapy, power injection of contrast media, and allows for central venous pressure monitoring.", "validation_result": "Supported", "page_location": "Page 2, Indications section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "PowerPICCT\u2122 Catheter. Offers versatility for multiple\ntherapies and CVP monitoring.18", "reference_no": "18", "reference": "BD PowerPICC: Instructions for Use (0735022).", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 18. 0735022 PowerPICC IFU.pdf: The PowerPICC* catheter is indicated for short or long term peripheral access to the central venous system for intravenous therapy, power injection of contrast media, and allows for central venous pressure monitoring.", "validation_result": "Supported", "page_location": "Page 2, Indications section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "PowerPICCT\u2122 Catheter. Designed to offer reliable vascular access. 18", "reference_no": "18", "reference": "BD PowerPICC: Instructions for Use (0735022).", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 18. 0735022 PowerPICC IFU.pdf: Catheters are packaged in a tray with accessories for reliable long (greater than 30 days) or short (less\nthan 30 days) term vascular access.", "validation_result": "Supported", "page_location": "Page 2, Product Description", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD\u00ae PowerGlide Pro\u2122\u2122 Midline Catheter. Provides a dwell time of up to 30 days. 10", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "BD\u00ae PowerGlide Pro\u2122\u2122 Midline Catheter. Allows access to deep veins by providing\na long catheter.10", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "BD\u00ae PowerGlide Pro\u2122\u2122 Midline Catheter. Helps reduce multiple catheter insertions\nin patients with difficult intravenous access. 10", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "Peripheral Venous Access. BD Instaflash\u2122\u2122\u2122 Needle\nTechnology for improved\nfirst-stick success. 19,20", "reference_no": "19,20", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 19. Seetharam-et-al-2022-a-randomized-controlled-study-to-compare-first-stick-success-with-instaflash-technology-the-firsst.pdf: The present study evaluated performance efficacy of BD Venflon\u2122 | with Instaflash needle technology (investigational device) as compared to the BD Venflon\u2122\u2122 without Instaflash needle technology (control device).|The present study showed that BD Venflon\u2122\u2122 | with Instaflash needle technology enhanced first attempt insertion success rate along with marginal differences in its efficacy in comparison with the BD Venflon\u2122\u2122 without Instaflash needle technology thus enhancing patient and nursing personnel satisfaction in turn making it a better alternative to be used in hospitals.\n- 20. Van Loon 2022 The impact of a notched peripheral intravenous catheter.pdf: In the intervention group, a Venflon\u2122 Pro Safety catheter with the InstaFlash\u2122\u2122 Needle Technology (notched needle) was inserted, whereas patients in the control group received a Venflon\u2122\u2122 Pro Safety catheter without the InstaFlash\u2122\u2122 Needle Technology (non-notched needle).", "validation_result": "Supported", "page_location": "Abstract | Page 4, Procedure and intervention", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Peripheral Venous Access. Blood Control\nTechnology to minimise\nblood exposure. 22", "reference_no": "22", "reference": "Onia R, Eshu-Wilson I, Arce C, et al. Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure. CMRO. 2011;27(7):1339-1346.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 22. Onia R. REF-17281 (11) Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous bl.pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Peripheral Venous Access. Its safety features reduce needlestick injuries and blood leakage.22", "reference_no": "22", "reference": "Onia R, Eshu-Wilson I, Arce C, et al. Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure. CMRO. 2011;27(7):1339-1346.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 22. Onia R. REF-17281 (11) Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous bl.pdf: The design of the safety PIVC-BC reduces blood leakage, and consequently has the potential to reduce the risk of HCW blood exposure during IV catheter insertion, removal of the needle and up until the initial luer connection.", "validation_result": "Supported", "page_location": "Page 7, Conclusion section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD Nexiva\u2122\u2122 Closed IV Catheter System. The BD Nexiva\u2122 Closed IV Catheter\nSystem is designed to enhance patient\ncomfort by improving insertion success\nwith BD Instaflash\u2122\u2122\u2122 Needle Technology,\nextending dwell times, and reducing\ncatheter-related complications. 15,19,20", "reference_no": "15,19,20", "reference": "", "matched_paper": "Multiple PDFs (2/3 support)", "matched_evidence": "- 19. Seetharam-et-al-2022-a-randomized-controlled-study-to-compare-first-stick-success-with-instaflash-technology-the-firsst.pdf: The present study evaluated performance efficacy of BD Venflon\u2122 | with Instaflash needle technology (investigational device) as compared to the BD Venflon\u2122\u2122 without Instaflash needle technology (control device).|The present study showed that BD Venflon\u2122\u2122 | with Instaflash needle technology enhanced first attempt insertion success rate along with marginal differences in its efficacy in comparison with the BD Venflon\u2122\u2122 without Instaflash needle technology thus enhancing patient and nursing personnel satisfaction in turn making it a better alternative to be used in hospitals.\n- 20. Van Loon 2022 The impact of a notched peripheral intravenous catheter.pdf: In the intervention group, a Venflon\u2122 Pro Safety catheter with the InstaFlash\u2122\u2122 Needle Technology (notched needle) was inserted, whereas patients in the control group received a Venflon\u2122\u2122 Pro Safety catheter without the InstaFlash\u2122\u2122 Needle Technology (non-notched needle).", "validation_result": "Supported", "page_location": "Abstract | Page 4, Procedure and intervention", "confidence_score": 0.875, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "BD Nexiva\u2122\u2122 Closed IV Catheter System. It has a built-in stabilization platform that helps reduce the risk\nof securement-related complications. 21", "reference_no": "21", "reference": "Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter-stabiliza- tion systems. J Infus Nurs. 2010;33(6):371-384.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 21. BD-1549 Bausone-Gazda D. A randomized controlled trial to compare the complications of 2.pdf: The investigational group catheter and stabilization protocol included the insertion of a BD Nexiva Closed IV Catheter System with a built-in stabilization platform and extension tubing with 2 split-septum access ports (Figure 2).", "validation_result": "Supported", "page_location": "Page 4, Investigational Group section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD Nexiva\u2122\u2122 Closed IV Catheter System. Helps mitigate risks to healthcare providers by preventing\nneedlestick injuries and blood exposure through its passive safety\nmechanism and closed integrated extension set. 11,21", "reference_no": "11,21", "reference": "", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 21. BD-1549 Bausone-Gazda D. A randomized controlled trial to compare the complications of 2.pdf: A closed catheter system (BD Nexiva Closed IV Catheter System, Becton, Dickinson and Company, Franklin Lakes, New Jersey) combines a PIV catheter with a built-in stabilization platform and a preattached extension tube exiting the hub at a 45-degree angle.", "validation_result": "Supported", "page_location": "Page 2, paragraph 6", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD Nexiva\u2122\u2122 Closed IV Catheter System. Optimised to increase dwell times, reduce catheter-related complications,\nand lower costs, leading to better healthcare outcomes. 15", "reference_no": "15", "reference": "Gonz\u00e1lez L\u00f3pez, J. L.et Al. (2014). Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. In Journal of Hospital Infection (Vol. 86, Issue 2, pp. 117\u2013126). doi.org/10.1016/j.jhin.2013.10.008.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 15. Gonz\u00e1lez L\u00f3pez 2014.pdf: This study shows the clear superiority of COS PIVCs over MOS PIVCs. | Indwell times were significantly longer for COS PIVCS, and phlebitis and infiltration rates were significantly lower, with an RRR for CRI, for only \u20ac0.09/day.", "validation_result": "Supported", "page_location": "Page 4, Discussion section", "confidence_score": 0.85, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD Venflon\u2122\u2122\u2122 Pro Safety Needle Protected IV Cannula. BD Vialon\u2122\u2122 catheter material is designed to enhance patient comfort\nby softening inthe vein, enabling longer dwell times. 23,24", "reference_no": "23,24", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 23. Kus B. REF-15004 Kus, Effectiveness of vialon biomaterial versus teflon catheters, 2019.pdf: This study concluded that vialon biomaterial catheter (BD Insyte\u2122 Autoguard\u2122\u2122 BC winged) demonstrates longer dwell time of PIVC, lower phlebitis rate and phlebitis score than teflon catheter (BD VenflonTM).\n- 24. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral ....pdf: Although most peripheral intravenous catheters used in the United States at present are made of a Teflon, catheters made of polyurethanes are available. | A novel catheter material, polyetherurethane (PEU) (PEU-Vialon, Becton Dickinson, Franklin Lakes, New Jersey) is based on polytetramethylene ether glycol, 4,4'-diphenyl-methane diiosocyanate, and 1,4-butanediol. | It does not require catalysts or stabilizers in its manufacture, has a smoother microsurface, and is thermoplastic and more hydrophilic, becoming much more flexible than Teflon at body temperature.", "validation_result": "Supported", "page_location": "Abstract, Conclusions | Page 2, column 2, paragraphs 1 and 2", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD Insyte\u2122 Autoguard\u2122 BC Pro Shielded IV Catheter\nwith Blood Control Technology. Softening capabilities of the BD Vialon\u2122\u2122 Catheter\nmaterial allows for longer dwell time and helps reduce\nphlebitis occurrence. 23,24,25", "reference_no": "23,24,25", "reference": "", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 23. Kus B. REF-15004 Kus, Effectiveness of vialon biomaterial versus teflon catheters, 2019.pdf: Conclusions: This study concluded that vialon biomaterial catheter\n(BD Insyte\u2122 Autoguard\u2122\u2122 BC winged) demonstrates longer dwell time of PIVC,\nlower phlebitis rate and phlebitis score than teflon catheter (BD VenflonTM).\n- 24. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral ....pdf: The best-fit model, using the 21 factors examined as potential predictors of phlebitis, showed the duration of catheter placement (> 2 days:\u2264 2 days, relative risk, 1.79; P < 0.001), sex (female:male, relative risk, 1.88; P < 0.001), use of the catheter for the administration of intravenous antibiotics (relative risk, 2.00; P < 0.001), and catheter material (PEU-Vialon:FEP-Teflon, relative risk, 0.73; P = 0.003) to be important predictors of infusion phlebitis in the study sample (Table 4).|In our comparative trial, catheters made of PEU-Vialon were substantially less phlebitogenic than were catheters made of FEP-Teflon: The reduction in risk was nearly 30% overall; in severe phlebitis, the reduction was nearly 50%.\n- 25. Gaukroger et al 1998.pdf: We conclude that the Insyte\u00ae cannulae (made from Vialon\u00ae) were significantly much less likely to develop infusion thrombophlebitis than the Jelco\u00ae cannulae (made from FEP-A Teflon\u00ae) in the two sizes tested (18 gauge and 16 gauge) and that, in this large prospective series involving 645 intravenous cannulae used in the operative and postoperative period, there were only a few factors which were otherwise found to increase the likelihood of infusion thrombophlebitis.", "validation_result": "Supported", "page_location": "Abstract | Page 6, Page 8 | Page 7, Discussion section, last paragraph", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "BD Insyte\u2122 Autoguard\u2122 BC Pro Shielded IV Catheter\nwith Blood Control Technology. Prevents needlestick injuries by automatically\nencapsulating the needle tip through its passive\nsafety mechanism.11", "reference_no": "11", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 11.INS 2024.pdf: None", "validation_result": "Not Found", "page_location": "The document does not mention the specific product BD Insyte\u2122 Autoguard\u2122 BC Pro Shielded IV Catheter with Blood Control Technology or its features.", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "BD Prevue II Vascular Access System. The BD Prevue II System is designed to enhance\nvascular access by providing ultrasound visualization,\nwhich may increase first-attempt success rate in\npatients, including those with DIVA.10", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "BD Prevue II Vascular Access System. Ultrasound visualization may improve\naccuracy and first stick access. 10", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "BD Prevue II Vascular Access System. Cue needle tracking technology is designed\nto provide precise needle guidance.10", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "BD Prevue II Vascular Access System. Compatible with Cue-enabled devices,\nincluding PowerGlide Pro Midline Catheters\nand AccuCath Ace Intravascular Catheters. 10", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "SiteRite \u00ae9 Ultrasound System. The SiteRite\u00ae 9 Ultrasound System is an all-in-one solution for\nvascular access device placement, compatible with the Sherlock\n3CG + Tip Confirmation System (TCS) for catheter tip tracking.26", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: The SiteRite\u2122 9 Ultrasound System is compatible with the following accessories: | Sherlock 3CG+\u2122 Tip Confirmation System (TCS)", "validation_result": "Supported", "page_location": "Page 6, Section 2.8", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "SiteRite \u00ae9 Ultrasound System. Vessel identification\n& measurement tools 26", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: 14.3.2 In-Plane Insertion", "validation_result": "Supported", "page_location": "Page 26, section 14.3.2", "confidence_score": 0.8, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "SiteRite \u00ae9 Ultrasound System. Real-time\nneedle tracking 26", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: 14.3.2 In-Plane Insertion", "validation_result": "Supported", "page_location": "Page 26, section 14.3.2", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "SiteRite \u00ae9 Ultrasound System. Patient data lookup\n+ & autofil| 26", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: 9.1.4 Patient Queue|Select Patient Queue to navigate to the Patient Queue screen. On this screen, enter patient information or access pre-entered patient information in the local queue.", "validation_result": "Supported", "page_location": "Page 13, Section 9.1.4 Patient Queue", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "SiteRite \u00ae9 Ultrasound System. Enhanced visuals\non 15.6\" screen 26", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "Entire document", "confidence_score": 0.1, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "SiteRite \u00ae9 Ultrasound System. Ergonomic probe\nwith button controls 26", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: SiteRite\u2122\u2122\u2122 9 Ultrasound System", "validation_result": "Supported", "page_location": "Title page of the document", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Sherlock 3CG+\u2122 + Surface Pro. For both adult and\npaediatric patients27", "reference_no": "27", "reference": "BD Sherlock 3CG+ Tip Confirmation System for us with SiteRite9 Ultrasound System: Instructions For Use (0755866)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 27. Sherlock 3CG+\u2122 Tip Confirmation System For use with SiteRite\u2122 9 Ultrasound System IFU (2).pdf: In adult patients and in adolescents (greater than 12 through 21 years of age), the Sherlock 3CG+\u2122 TCS can be used with CVADS such as peripherally inserted central catheters (PICCs), central venous catheters (CVCs), implantable ports, and hemodialysis catheters.|In children (greater than 2 to 12 years of age), in infants (greater than 1 month to 2 years of age), and in neonates (from birth to 1 month of age), the Sherlock 3CG+\u2122 TCS can be used with PICCs and with centrally inserted central catheters (CICCs).", "validation_result": "Supported", "page_location": "Page 2, Section 1.1 Indications for Use", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Sherlock 3CG+\u2122 + Surface Pro. Using an identifiable\nP-wave27", "reference_no": "27", "reference": "BD Sherlock 3CG+ Tip Confirmation System for us with SiteRite9 Ultrasound System: Instructions For Use (0755866)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 27. Sherlock 3CG+\u2122 Tip Confirmation System For use with SiteRite\u2122 9 Ultrasound System IFU (2).pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Sherlock 3CG+\u2122 + Surface Pro. It offers an alternative method to chest X-ray fluoroscopy for\nCVAD tip placement, avoiding exposure to harmful radiation.27", "reference_no": "27", "reference": "BD Sherlock 3CG+ Tip Confirmation System for us with SiteRite9 Ultrasound System: Instructions For Use (0755866)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 27. Sherlock 3CG+\u2122 Tip Confirmation System For use with SiteRite\u2122 9 Ultrasound System IFU (2).pdf: The Sherlock 3CG+\u2122 TCS provides real-time catheter tip location information by using catheter navigation technology along with the patient's cardiac electrical activity and is indicated for use as an alternative method to chest X-ray and fluoroscopy for CVAD tip placement confirmation of approaches from the superior vena cava.", "validation_result": "Supported", "page_location": "Page 2, Section 1.1 Indications for Use", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD ChloraPrep\u2122\u2122 is a skin antisepsis solution designed to optimise skin preparation and reduce\ninfection risk. It features a single-use, non-touch applicator containing 2% w/v chlorhexidine\ngluconate (CHG) and 70% v/v isopropyl alcohol (IPA) in a sterile applicator. 28", "reference_no": "28", "reference": "Ostrander RV, Botte MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87(5):980\u2013985.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 28. Ostrander 2005.pdf: Each lower extremity was prepared with one of three randomly selected solutions: DuraPrep (0.7% iodine and 74% isopropyl alcohol), Techni-Care (3.0% chloroxylenol), or ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol).", "validation_result": "Supported", "page_location": "Page 1, Methods section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "ChloraPrep\u2122\u2122 Skin Preparation. Effective antimicrobial action. 28", "reference_no": "28", "reference": "Ostrander RV, Botte MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87(5):980\u2013985.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 28. Ostrander 2005.pdf: Conclusions: The use of effective preoperative preparation solution is an important step in limiting surgical wound contamination and preventing infection, particularly in foot and ankle surgery. |Of the three solutions tested in the present study, the combination of chlorhexidine and alcohol (ChloraPrep) was most effective for eliminating bacteria from the forefoot prior to surgery.", "validation_result": "Supported", "page_location": "Page 1, Conclusions section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "ChloraPrep\u2122\u2122 Skin Preparation. Can reduce colonisation of peripheral IV catheter tips by 60%.29", "reference_no": "29", "reference": "Small H, Adams D, Casey A L, et al. Efficacy of adding 2% (w/v) chlorhexidine gluconate to 70% (v/v) isopropyl alcohol for skin disinfection prior to peripheral venous cannulation. Infect Control Hosp Epidemiol. 2008;29:963\u2013965.30. Madeo M, Barlow G. Reducing blood-culture contamination rates by the use of a 2% chlorhexidine solution applicator in acute admission units.JHosp Infect.2008;69:307\u2013309.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 29. Small et al. 200.pdf: The use of 2% CHG in IPA was associated with a reduced number of PVC tips with microorganisms present on their surface, compared with the use of 70% IPA alone (Figure).|Microorganisms were present on 39 (49.4%) of 79 PVC tips in the 70% IPA group, compared with 18 (19.8%) of 91 PVC tips in the 2% CHG in IPA group (P < .001; odds ratio, 4.0 [95% confidence interval, 2.0\u20137.8]).", "validation_result": "Supported", "page_location": "Page 3, Results section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "ChloraPrep\u2122\u2122 Skin Preparation. Can decrease blood culture contamination rates by 72%.30", "reference_no": "30", "reference": "", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 30. Madeo et al 2008.pdf: No evidence found in the paper.", "validation_result": "Not Found", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "The BD StatLock\u2122\u2122 Stabilization Device portfolio provides\nspecialised solutions for arterial, epidural, dialysis, central venous,\nand peripheral IV catheters. 31,32 These devices can improve clinical\noutcomes by enhancing overall care quality. They are designed to:", "reference_no": "31,32", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 31. StatLock IFU.pdf: StatLock* device is a stabilization device for compatible winged catheters.\n- 32. BD-142264 StatLock Stabilization Device Presentation.pdf: BD provides a complete vascular access securement portfolio\nto help support optimized vascular device and catheter maintenance|BD StatLock\u2122 PIVC\nStabilization Devices\nStatLock\u2122 PIVC Stabilization Devices are\nuniversally compatible with all BD peripheral\nIV catheters' - available in adult and pediatric\nsizes and shown to reduce IV therapy\ncomplications and the resulting unplanned\nIV restarts to improve patient care. 1|BD StatLock\u2122 Midline\nStabilization Devices\nStatLock\u2122 Pro Catheter Stabilization Devices\nare designed for the BD PowerGlide\u2122\nPro Midline Catheter Hub.|BD StatLock\u2122 PICC Plus\nStabilization Devices\nStatLock\u2122 PICC Stabilization Devices are a\n\"post and door\" design to house the suture\nwings of virtually all peripherally inserted\ncentral catheters (PICCs).|BD StatLock\u2122 CVC\nStabilization Devices\nStatLock\u2122 CVC Stabilization Devices are\ndesigned to help reduce sharp injuries to\nhealthcare workers when they are securing\ncentral line catheters, in comparison to\nsuture stabilization.|BD StatLock\u2122 Universal\nStabilization Devices\nStatLock\u2122 Universal Plus Stabilization\nDevices are used for percutaneous\ndrainage catheters.|BD StatLock\u2122 Arterial Plus\nStabilization Devices\nStatLock\u2122 Arterial Stabilization Devices offer\nboth a patented luer lock extension set\n(for universal compatibility with all arterial\ncatheters) and clamshell retainer for ease\nof use.|BD StatLock\u2122 Dialysis\nStabilization Devices\nStatLock\u2122 Dialysis Stabilization Devices\nare sutureless stabilization devices offering\na safer alternative to suture securement.|BD StatLock\u2122 Epidural\nStabilization Devices\nStatLock\u2122 Epidural Stabilization Devices provide\na range of epidural stabilization tailored to help\nprevent issues and designed to ensure\ncontinuous and effective anesthesia.", "validation_result": "Supported", "page_location": "Page 1, Indications for Use | Page 13", "confidence_score": 0.8999999999999999, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD StatLock\u2122\u2122 Stabilization Devices. Reduce\nneedlestick risks33", "reference_no": "33", "reference": "Schears GJ. Summary of product trials for 10, 164 patients: comparing an intravenous stabilizing device to tape. J Infus Nurs. 2006;29(4):225-31.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 33. REF-14260 Schears_Summary_of_Product_Trials_for_10_164_Patients_.9 (1).pdf: Newer catheter-stabilizing technologies can help to reduce patient complications, for an overall cost savings, and consequently reduce needlestick exposures for healthcare providers by reducing restarts and prolonging dwell times.", "validation_result": "Supported", "page_location": "Page 225, Abstract", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD StatLock\u2122\u2122 Stabilization Devices. Reduce\ncomplications 21,33", "reference_no": "21,33", "reference": "", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 33. REF-14260 Schears_Summary_of_Product_Trials_for_10_164_Patients_.9 (1).pdf: The rates for total complications, including occlusion, dis- lodgment, infiltration, extravasation, and phlebitis, were also significantly different between the 2 groups (Table 2).|The complication rate was 47.6% in the tape group and 16% in the stabilization device group. This represents approximately a 67% decrease in the total complications.", "validation_result": "Supported", "page_location": "Page 3, Total Complications section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD StatLock\u2122\u2122 Stabilization Devices. Enhance\npatient safety 21", "reference_no": "21", "reference": "Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter-stabiliza- tion systems. J Infus Nurs. 2010;33(6):371-384.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 21. BD-1549 Bausone-Gazda D. A randomized controlled trial to compare the complications of 2.pdf: The control stabilization system included the StatLock device with a nonwinged catheter, and the investigational stabilization system included a closed catheter system with a specially designed Tegaderm dressing.", "validation_result": "Supported", "page_location": "Page 1, Abstract", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. Intended for maintaining vascular access device patency, BD PosiFlush\u2122\u2122 SP is designed\nfor use with peripheral intravenous catheters (PIVCs), central venous catheters (CVCs),\nperipherally inserted central catheters (PICCs), and implanted venous access ports. 34,35", "reference_no": "34,35", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 34. REF-55071 BD PosiFlush XS IFU 500067397 Rev. 2022-12.pdf: Intended for FLUSHING ONLY of in-situ PIVCs, PICCs, CVCs, and implanted venous access ports.\n- 35. REF-64684 IFU PosiFlush SP 10000223600 rev 06.pdf: - BD PosiFlush\u2122 SP Syringes are intended to be used FOR FLUSHING ONLY of in-situ peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs), central venous catheters (CVCs), and implanted venous access ports.", "validation_result": "Supported", "page_location": "Page 1, under the section with title 'ENGLISH INSTRUCTIONS FOR USE' | Page 2, under the heading \"INTENDED USE/INDICATIONS FOR USE\"", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. BD PosiFlush\u2122\u2122\u2122 XS syringe is intended to minimise contamination in a sterile field. 11,36", "reference_no": "11,36", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 11.INS 2024.pdf: BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes.\n- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: May be used on sterile fields. Provided in sterile packaging.", "validation_result": "Supported", "page_location": "Appears in the list of reviewers on page 3. | Page 14, BD PosiFlush\u2122\u2122 XS Normal Saline Prefilled Syringe description", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. Sterile saline.36", "reference_no": "36", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush\u2122\u2122 SP Saline Prefilled Syringe|BD PosiFlush\u2122\u2122 XS Normal Saline Prefilled Syringe", "validation_result": "Supported", "page_location": "Page 14, product overview", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. A consistent 10 mL barrel\ndiameter to help lower\ncatheter damage risk. 11,36", "reference_no": "11,36", "reference": "", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush Pre-Filled Syringes have a consistent 10mL syringe barrel diameter which may help lower the risk of catheter damage due to injection pressure", "validation_result": "Supported", "page_location": "Page 12, under the 'Consistent 10 ml syringe diameter' feature", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. Optimised design available in\n3 mL, 5 mL, and 10 mL sizes.36", "reference_no": "36", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: Available: 3 mL, 5 mL, 10mL", "validation_result": "Supported", "page_location": "Page 14, under BD PosiFlush\u2122\u2122 SP Saline Prefilled Syringe and BD PosiFlush\u2122\u2122 XS Normal Saline Prefilled Syringe", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. The stopper is designed to\nreduce blood reflux, thereby\nimproving clinical efficiency\nand reducing complications\nduring flushing procedures. 36,37", "reference_no": "36,37", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush\u2122\u2122 Prefilled Syringe stopper is designed to reduce the likelihood of syringe-induced catheter reflux\n- 37. Hadaway Lynn.pdf: Use of prefilled syringes designed to pre-vent this rebound problem may enhance catheter lumen patency.", "validation_result": "Supported", "page_location": "Page 12, under the 'Stopper' feature | Page 4, paragraph discussing syringe and fluid flow dynamics inside the catheter", "confidence_score": 0.875, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD Q-Syte\u2122 Needle-free Connector. The split-septum design of the BD Q-Syte\u2122\u2122\u2122\nNeedle-free Connector minimises CRBSI risk\nwhen used as part of a CRBSI prevention bundle\nand is preferred over mechanical valves. 41", "reference_no": "41", "reference": "Centers for Disease Control and Prevention (CDC). O\u2019Grady NP, Alexander M, Burns LA, et al.; Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 41. Guideline-BSI-H.pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "", "confidence_score": 0.1, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "BD Q-Syte\u2122 Needle-free Connector. Using prefilled flushed syringes (BD Posiflush) with a needle-free connector\n(BD Q-syte) have shown CLABSI rate reduction of 65% and cost savings\ncompared to the use of a three-way stopcock and standard flushing. 42", "reference_no": "42", "reference": "Rosenthal VD, Udwadia FE, Kumar S, et al. Clinical impact and cost effectiveness of split-septum and single-use prefilled flushing device vs 3-way stopcock on central-line associated bloodstream infection rates in India: a randomized clinical trial conducted by the International Nosocomial Infection Control Consortium (INICC). Am J Infect Control. 2015;43(10):1040\u20131045.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 42. Rosenthal et al.pdf: The results for average process costs were statistically significantly lower for the closed access system (SS) than for the luer lock caps (3WSC) (\u20ac2.55 vs \u20ac3.92).|This is the first RCT to examine the effect of using SS + SUF vs 3WSC on the incidence rate of CLABSI and to assess the cost-effectiveness of the 2 types of devices, which is sufficient ethical and theoretical justification for conducting this particular trial and, through its publication, increasing and spreading awareness on this public health burden in India-the second largest country of the world, with a population of approximately 1,300,000,000 people, as well as throughout the developing world where 3WSCs are in use.", "validation_result": "Supported", "page_location": "Page 2, Introduction and Page 2, Methods", "confidence_score": 0.85, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD Q-Syte\u2122 Needle-free Connector. Maximum flow rate of 32 L/hr enables diverse clinical applications.43", "reference_no": "43", "reference": "BD Q-Syte Technical Data Sheet", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 43. BD Q-Syte TDS.pdf: Maximum Flow Rate 32 L/hr", "validation_result": "Supported", "page_location": "Page 1, Technical Information section", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 Heparin and Lock Flush Syringe. The BD PosiFlush\u2122 Heparin and Lock Flush Syringe is a prefilled syringe designed to support\nsafe and effective catheter care. 36,38", "reference_no": "36,38", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush\u2122\u2122 Prefilled Flush Syringes are manufactured using a fully-automated, manufacturing process - from components to formulation to filling to packaging with no third-party involvement.\n- 38. REF-17199 PosiFlush HL IFU.pdf: BD PosiFlush\u2122\u2122 Heparin Lock Flush Syringe", "validation_result": "Supported", "page_location": "Page 7 | Page 1, top left corner and page 2, Dosage and Administration section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 Heparin and Lock Flush Syringe. Intended to maintain patency of vascular access\ndevices only. 36,38", "reference_no": "36,38", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: Intended for maintenance of patency of vascular access devices only.\n- 38. REF-17199 PosiFlush HL IFU.pdf: BD PosiFlush\u2122\u2122 Heparin Lock Flush Syringes are intended for maintenance of patency of vascular access devices only.", "validation_result": "Supported", "page_location": "Page 14, under the description of BD PosiFlush\u2122\u2122 Heparin & Citrate Lock Flush Syringe | Page 1, Indications and Usage", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 Heparin and Lock Flush Syringe. Increases PIVC dwell time.36", "reference_no": "36", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: Increased catheter dwell time", "validation_result": "Supported", "page_location": "Page 11, under the section titled \"BD PosiFlush\u2122 has more published clinical studies than any other product in the prefilled flush category\"", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 Heparin and Lock Flush Syringe. Consistent 10 mL barrel diameter to help lower\ncatheter damage risk. 11,36", "reference_no": "11,36", "reference": "", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush Pre-Filled Syringes have a consistent 10mL syringe barrel diameter which may help lower the risk of catheter damage due to injection pressure", "validation_result": "Supported", "page_location": "Page 12, under the feature 'Consistent 10 ml syringe diameter'", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD MaxPlus\u2122\u2122 Needle-free Connector and BD MaxZero\u2122\u2122\nNeedle-free Connector. BD MaxPlus\u2122\u2122 and BD MaxZero\u2122\u2122 use the same\nneedle-free connector technology, supported by\na meta-analysis showing reduced CLABSI risk. 39,40", "reference_no": "39,40", "reference": "", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 39. Tabak2014.pdf: Our meta-analysis demonstrated that the study NC with improved engineering design features that facilitate effective dis-infections was associated with a lower risk of CLA-BSI.\n- 40. BD-66381 Needle-free Connectors Playbook FINAL 11.2022 (1).pdf: \u2022 BD MaxPlus\u2122 Needle-free Connector: Backed by a meta-analysis\n(one of the most rigorous levels of evidence in the scientific community)\ndemonstrating reduced risk of CLABSI,2 supported with this FDA-cleared\nlabel statement*:\n\u2022 BD MaxZero\u2122\u2122 Needle-free Connector: The same technology in a smaller\nsize, with lower weight and reduced priming volume, making it appropriate\nfor infants and children", "validation_result": "Supported", "page_location": "Page 4, Discussion section, first paragraph | Page 8, Our NFC portfolio", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD MaxPlus\u2122\u2122 Needle-free Connector and BD MaxZero\u2122\u2122\nNeedle-free Connector. Uses positive displacement to expel fluid upon\ndisconnection to help reduce occlusions. 40", "reference_no": "40", "reference": "BD-66381 Needle-free Connectors Playbook.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 40. BD-66381 Needle-free Connectors Playbook FINAL 11.2022 (1).pdf: Get to know our portfolio of\nneedle-free connectors: MaxPlus\u2122\u2122,\nMaxZero\u2122\u2122, Q-Syte\u2122\u2122 and SmartSite\u2122\u2122", "validation_result": "Supported", "page_location": "Page 5, under the 'Position' section of the BD NFC implementation process", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD MaxPlus\u2122\u2122 Needle-free Connector and BD MaxZero\u2122\u2122\nNeedle-free Connector. Features a proprietary flat surface that helps\nprevent contamination and bacterial entry when\ndisinfected with a 3-second scrub using 70% IPA.40", "reference_no": "40", "reference": "BD-66381 Needle-free Connectors Playbook.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 40. BD-66381 Needle-free Connectors Playbook FINAL 11.2022 (1).pdf: The only technology\nwith a patented flat,\nsealed, solid surface\nthat helps prevent\ncontamination and\nbacteria from entering\nthe connector when\ndisinfected with a\n3-second scrub using\n70% IPA", "validation_result": "Supported", "page_location": "Page 37, detail aids for all BD NFCs, BD Max needle-free connector technology", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PureHub\u2122\u2122\u2122 Disinfecting Cap. BD PureHub\u2122\u2122\u2122 Disinfecting Cap is designed to provide rapid disinfection and maintain\na physical barrier against contamination.44", "reference_no": "44", "reference": "BD-92271 Infection Prevention Clinical Compendium EMEA DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed Tomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter; CVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter; CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted Central Catheter; ECG: Electrocardiogram", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 44. BD-92271_Infection_Prevention_Clinical_Compendium_EMEA.pdf: BD PureHub\u2122\u2122\u2122 Disinfecting Cap demonstrated in-vitro, a 99.99% (>4 log) reduction on the most common causative agents in CRBSI including: Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Candida glabrata, Candida albicans, Acinetobacter baumannii.*|Maintains a physical barrier to contamination for up to 7 days, if not removed++", "validation_result": "Supported", "page_location": "Page 15, under the heading \"BD PureHub\u2122 Disinfecting Cap\"", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PureHub\u2122\u2122\u2122 Disinfecting Cap. Disinfects with a sterilised\n70% IPA solution.44", "reference_no": "44", "reference": "BD-92271 Infection Prevention Clinical Compendium EMEA DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed Tomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter; CVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter; CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted Central Catheter; ECG: Electrocardiogram", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 44. BD-92271_Infection_Prevention_Clinical_Compendium_EMEA.pdf: Disinfects with a sterilised 70% isopropyl alcohol solution", "validation_result": "Supported", "page_location": "Page 15, under the heading \"BD PureHub\u2122 Disinfecting Cap\"", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PureHub\u2122\u2122\u2122 Disinfecting Cap. Rapid disinfection in 60 seconds.44", "reference_no": "44", "reference": "BD-92271 Infection Prevention Clinical Compendium EMEA DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed Tomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter; CVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter; CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted Central Catheter; ECG: Electrocardiogram", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 44. BD-92271_Infection_Prevention_Clinical_Compendium_EMEA.pdf: Rapid disinfection in just 60seconds 27,28", "validation_result": "Supported", "page_location": "Page 15, under the heading \"BD PureHub\u2122 Disinfecting Cap\"", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PureHub\u2122\u2122\u2122 Disinfecting Cap. Provides 99.99% (>4 log) reduction\nin common pathogens.44", "reference_no": "44", "reference": "BD-92271 Infection Prevention Clinical Compendium EMEA DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed Tomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter; CVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter; CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted Central Catheter; ECG: Electrocardiogram", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 44. BD-92271_Infection_Prevention_Clinical_Compendium_EMEA.pdf: BD PureHub\u2122\u2122\u2122 Disinfecting Cap demonstrated in-vitro, a 99.99% (>4 log) reduction on the most common causative agents in CRBSI including: Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Candida glabrata, Candida albicans, Acinetobacter baumannii.*", "validation_result": "Supported", "page_location": "Page 15, under the heading \"BD PureHub\u2122 Disinfecting Cap\"", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PureHub\u2122\u2122\u2122 Disinfecting Cap. Maintains a physical barrier against\ncontamination if not removed for up to 7 days.44", "reference_no": "44", "reference": "BD-92271 Infection Prevention Clinical Compendium EMEA DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed Tomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter; CVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter; CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted Central Catheter; ECG: Electrocardiogram", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 44. BD-92271_Infection_Prevention_Clinical_Compendium_EMEA.pdf: Maintains a physical barrier to contamination for up to 7 days, if not removed++", "validation_result": "Supported", "page_location": "Page 15, under the image of the BD PureHub\u2122 Disinfecting Cap", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}], "created_at": "2026-02-10T09:58:16.805162"}